by Sermonix Pharmaceuticals | Nov 28, 2023 | News
COLUMBUS, Ohio, Nov. 28, 2023 (GLOBE NEWSWIRE) — Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company developing innovative therapeutics to specifically treat metastatic breast cancers harboring ESR1 mutations, today announced that it had...
by Sermonix Pharmaceuticals | Nov 8, 2023 | News
Dr. Einav Nili Gal-Yam, head of the Breast Oncology Institute at Chaim Sheba Medical Center, was the principal investigator COLUMBUS, Ohio, Nov. 06, 2023 (GLOBE NEWSWIRE) — Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company developing...
by Sermonix Pharmaceuticals | Oct 2, 2023 | News
Results showed that younger age, non-visceral disease, prior tamoxifen and a longer total duration of AI use may be associated with higher baseline vaginal and/or vulvar symptomatology Findings were presented in a poster at The Menopause Society 2023 Annual Meeting...
by Sermonix Pharmaceuticals | Oct 2, 2023 | News
More than 60% of survey respondents experienced vaginal symptoms and felt their sexual health was negatively impacted by prior endocrine therapy About half never or almost never felt sexual desire or interest in the previous month, particularly those whose sexual...
by Sermonix Pharmaceuticals | Sep 5, 2023 | News
COLUMBUS, Ohio, Sept. 05, 2023 (GLOBE NEWSWIRE) — Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company developing innovative therapeutics to specifically treat metastatic breast cancers harboring ESR1 mutations, today announced it shared an...
by Sermonix Pharmaceuticals | Jun 30, 2023 | News
One poster examines baseline vaginal and vulvar symptoms in ESR1-mutated, ER+/HER2- metastatic breast cancer Second poster shares survey results examining vaginal and sexual health in ER+/HER2- metastatic breast cancer patients COLUMBUS, Ohio, June 29, 2023 (GLOBE...
Recent Comments